- Home
- MDGL vs AES Comparison
MDGL vs AES Comparison
Compare MDGL & AES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MDGL | AES |
|---|---|---|
| Founded | 2011 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1B | 9.9B |
| IPO Year | 2005 | 1996 |
Fundamental Metrics
Financial Performance| Metric | MDGL | AES |
|---|---|---|
| Price | $549.60 | $14.77 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 10 |
| Target Price | ★ $674.45 | $15.29 |
| AVG Volume (30 Days) | 306.0K | ★ 7.3M |
| Earning Date | 05-06-2026 | 05-01-2026 |
| Dividend Yield | N/A | ★ 4.87% |
| EPS Growth | ★ 41.32 | N/A |
| EPS | N/A | ★ 0.68 |
| Revenue | $180,133,000.00 | ★ $12,233,000,000.00 |
| Revenue This Year | $58.39 | $5.22 |
| Revenue Next Year | $48.55 | $4.81 |
| P/E Ratio | ★ N/A | $21.51 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $286.75 | $12.33 |
| 52 Week High | $615.00 | $17.65 |
Technical Indicators
Market Signals| Indicator | MDGL | AES |
|---|---|---|
| Relative Strength Index (RSI) | 61.89 | 63.46 |
| Support Level | $498.59 | $14.59 |
| Resistance Level | $572.20 | $15.02 |
| Average True Range (ATR) | 21.95 | 0.07 |
| MACD | 5.25 | 0.00 |
| Stochastic Oscillator | 77.24 | 84.21 |
Price Performance
Historical ComparisonAbout MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
About AES The AES Corporation
AES is a global power company that operates in 15 countries. Its generation portfolio totals over 32 gigawatts, including renewable energy (50%), gas (32%), coal (16%), and oil (2%). AES has majority ownership and operates six electric utilities distributing power to more than 2.5 million customers.